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Abstract 24 
Background: Increased firing across glutamatergic synapses may contribute to both the motor 25 
dysfunction and L-DOPA-induced dyskinesia seen in Parkinson’s disease.  Given their ability to 26 
reduce glutamate release, activation of group III metabotropic glutamate receptors such as 27 
metabotropic glutamate receptor 4 may prove effective against both motor dysfunction and 28 
dyskinesia in Parkinson’s disease.   29 
 30 
Objectives: We hypothesised that activation of metabotropic glutamate receptor 4 by an orthosteric 31 
agonist ((2S)-2-amino-4-(hydroxy(hydroxy(4-hydroxy-3-methoxy-32 
nitrophenyl)methyl)phosphoryl)butanoic acid, LSP1-2111) would produce antiparkinsonian activity 33 
and reduce expression of dyskinesia in a 1-methyl-4-phenyl,1,2,3,6-tetrahydropyridine (MPTP)-34 
treated marmoset model of Parkinson’s disease. 35 
 36 
Methods: Common marmosets were previously treated with MPTP and pre-primed with L-DOPA for 37 
up to 28 days to express dyskinesia. LSP1-2111 (1, 3 or 6 mg/kg s.c.) or vehicle (0.9% saline s.c.) were 38 
administered immediately prior to L-DOPA (8 mg/kg + benserazide (10 mg/kg) p.o.) or vehicle (10% 39 
sucrose p.o.). Locomotor activity was measured in automated test cages and animals were scored 40 
for dyskinesia and disability. 41 
 42 
Results: As expected, L-DOPA reversed motor disability and induced moderate dyskinesia. By 43 
contrast, LSP1-2111 alone significantly reduced the motor disability without any accompanying 44 
expression of dyskinesia. When administered in combination with L-DOPA, LSP1-2111 did not 45 
significantly reduce the severity of L-DOPA-induced dyskinesia. 46 
 47 
Conclusions: Systemic administration of LSP1-2111 reduces motor disability without causing 48 
dyskinesia in MPTP-treated marmosets, supporting a role for metabotropic glutamate receptor 4 49 
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orthosteric agonists as promising monotherapy for PD. Conversely, this study found no evidence to 50 
support their use as antidyskinetic agents within the dose range tested.  51 
 52 
Key words: dyskinesia; levodopa; motor disability; Parkinson’s disease 53 
 54 
Introduction 55 
Parkinson’s disease (PD) is a progressive neurodegenerative disorder that presents with motor (e.g. 56 
bradykinesia, tremor and postural instability) and non-motor (e.g. pain, anxiety and REM-sleep 57 
behaviour disorder) symptoms. The current gold standard treatment for PD is L-3,4-58 
dihydroxyphenylalanine (L-DOPA), which provides relief from motor symptoms. However, within 4-6 59 
years after the initiation of L-DOPA treatment, 40% of PD patients experience unwanted involuntary 60 
movements in the form of L-DOPA-induced dyskinesia (LID) of a choreic or dystonic nature[1]. 61 
 62 
Increased glutamatergic transmission has been implicated in the pathophysiology of both 63 
parkinsonian motor symptoms and L-DOPA-induced dyskinesia[2,3]. Increased transmission across 64 
the glutamatergic subthalamonigral pathway is believed to contribute towards manifestation of the 65 
motor symptoms[4,5] while plasticity of the glutamatergic corticostriatal pathway is implicated in 66 
the development of LID[6–9]. In support of the glutamatergic involvement in LID, the weak N-67 
methyl-D-aspartate (NMDA) receptor antagonist amantadine is one of very few drugs shown to have 68 
any efficacy against LID[10–13]. However, amantadine has a poor side-effect profile involving 69 
psychiatric problems such as hallucination, confusion and depression[14] which reduces its 70 
therapeutic utility. An alternative route to the glutamatergic modulation of signalling for potential 71 
therapeutic benefit against both the parkinsonian motor symptoms and LID is to target 72 
metabotropic glutamate receptors, specifically, the group III metabotropic glutamate receptors 73 
(mGluRs) which have shown promise in a range of PD and LID indications[2,3,15]. 74 
 75 
4 
 
Group III mGluRs are Gi/o-coupled, presynaptic receptors which reduce exocytosis of 76 
neurotransmitter in response to activation by endogenous glutamate[16–18]. One member of this 77 
family, mGluR4, has received attention as a potential therapeutic target in PD due to its expression 78 
at relevant synapses throughout the basal ganglia[15,19–21]. Indeed, both agonists and positive 79 
allosteric modulators (PAMs) of mGluR4 have been shown to provide antiparkinsonian effects in 80 
acute models of PD in rodents[22–25], while PAMs offer antiparkinsonian relief in a 1‐methyl‐4‐81 
phenyl‐1,2,3,6‐tetrahydropyridine (MPTP)-treated macaque model of PD[26]. 82 
 83 
Studies have also shown the antidyskinetic potential of targeting mGluR4. Thus, the mGluR4 PAM, 84 
(1S, 2R)-N1-(3,4-dichlorophenyl)-cyclohexane-1,2-dicarboxamide (Lu AF219234), reduced the 85 
development of L-DOPA-induced abnormal involuntary movements (AIMs) in rodent models of 86 
LID[24]. Similarly, the mGluR4 PAM, Foliglurax (PXT002331), reduced the expression of well-87 
established LID in the MPTP-treated macaques[26]. A systemically-active agonist of mGluR4, (2S)-2-88 
amino-4-(hydroxy(hydroxy(4-hydroxy-3-methoxy-nitrophenyl)methyl)phosphoryl)butanoic acid 89 
(LSP1-2111) has also shown efficacy against the development of L-DOPA-induced AIMs in 90 
rodents[27]. However, whether an mGluR4 agonist will offer beneficial effects in a primate model of 91 
PD remains to be examined. This study therefore set out to establish whether the mGluR4 agonist 92 
LSP1-2111 provides antiparkinsonian relief in an MPTP-treated marmoset model of PD and whether 93 
it also reduces the expression of established LID in this model. 94 
 95 
Materials & Methods  96 
Animals 97 
Common marmosets (Callithrix jacchus, Harlan, Loughborough, LE12 9TE, UK and Manchester 98 
University, UK) aged 7–14 years were housed in female/male (vasectomised) or female/female pairs 99 
at a temperature of 23  2 0C with 50% relative humidity and a 12 hour light/dark cycle[28,29]. They 100 
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had unlimited access to water and marmoset pellets and received one meal of mashed cereal and 101 
one meal of fresh fruit daily. All experiments were performed according to the Animals (Scientific 102 
Procedures Act) 1986 under Project Licence No 70/8541, with local approval of the Animal Welfare 103 
and Ethical Review Board of King’s College London and were compliant with the minimum standards 104 
as defined by the European Communities Council Directive (10/63/EU). All animals involved in this 105 
study had previously been included in studies assessing the therapeutic value of compounds in PD 106 
and LID. Following previous studies, all animals underwent a drug-free ‘washout’ period of at least 4 107 
weeks before the start of this study. 108 
 109 
MPTP-Treatment 110 
Five to seven years prior to this study, marmosets underwent administration of MPTP (Sigma, UK) at 111 
2.0 mg/kg daily for 5 days to induce stable motor deficits [30,31]. This resulted in the animals 112 
exhibiting reduced basal locomotor activity, bradykinesia, rigidity, poor coordination of movement 113 
and reduced alertness/awareness. All animals were primed to express dyskinesia on exposure to L-114 
DOPA through repeated (up to 28 days) oral administration of L-DOPA (8-12.5 mg/kg, Sigma, UK) 115 
plus benserazide (10mg/kg, Sigma, UK) in a 10% sucrose solution. 116 
 117 
Drug Treatment 118 
Animals (n=8) were selected for the study from a pool (n=10) of MPTP-treated marmosets based on 119 
their response to L-DOPA treatment. For this selection process L-DOPA (4, 6 and 8 mg/kg) plus 120 
benserazide (10 mg/kg) was administered p.o. and locomotor activity recorded (as detailed below). 121 
L-DOPA (8 mg/kg) was selected as the dose (providing approximately 70% of a maximal response) for 122 
use in the main part of the study. Two animals were removed from the study prior to completion for 123 
welfare reasons unrelated to the study, leaving a final group size of n=6 (3 male and 3 female). 124 
 125 
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A modified Latin square design was used to randomise treatments whilst ensuring dosing with LSP1-126 
2111 (Lundbeck, Denmark) occurred in a dose-escalating manner, to identify any side-effects before 127 
higher doses were given. In this fashion, each animal received all drug combinations once (with an 128 
interval of ≥48 hours between doses). LSP1-2111 was administered subcutaneously in 0.9% sterile 129 
saline (Baxter healthcare) at 0 (vehicle) 1, 3 or 6 mg/kg in a volume of 1 ml/kg. The lowest dose for 130 
LSP1-2111 (1 mg / kg) was selected based on previous data showing emerging significant effects in a 131 
range of behavioural tests in rodents with this dose [25,32].  132 
 133 
Following a 60 min acclimatisation period, baseline motor function (locomotor activity, motor 134 
disability and dyskinesia) was assessed for 60 min as described below.  Following the 60 min baseline 135 
assessment, LSP1-2111 and L-DOPA (or respective vehicles) were administered according to the 136 
randomisation protocol. LSP1-2111 (1, 3 or 6 mg/kg s.c.) or vehicle (1 ml/kg s.c.) was administered 137 
immediately followed by L-DOPA (8 mg/kg plus benserazide (10 mg/kg)) or vehicle (10% sucrose plus 138 
benserazide (10 mg/kg)) in a combined p.o. administration of 2 ml/kg.  139 
 140 
Behavioural measurements 141 
On test days, animals were acclimatised for 60 min to individual automated test units (50 cm by 60 142 
cm by 90 cm).  The automated test units were fitted with 2 horizontal wooden perches and a water 143 
supply and a clear Perspex door to allow visual observation. Food was not provided during the test 144 
period and animals received their normal meal at the end of the test period on return to home 145 
caging. Locomotor activity, motor disability and dyskinesia were assessed for up to 6 hours as 146 
described below.  147 
 148 
Locomotor activity 149 
Each behavioural test unit was fitted with 8 photoelectric emitters/detectors (light beams) arranged 150 
horizontally to permit optimal assessment of locomotor activity.   Interruption of a light beam was 151 
7 
 
automatically recorded as a single locomotor count which were accumulated in 30 min time 152 
segments for 1 hour before and 5 hours following drug treatment.  153 
 154 
Motor disability 155 
Motor disability was assessed simultaneously with locomotor activity, by observation via a one-way 156 
mirror, by experienced observers blinded to the treatment. Basal disability was assessed once every 157 
30 minutes, for 30 minutes before and 5 hours after drug treatment using an established motor 158 
disability rating scale; alertness (normal = 0, reduced = 1, sleepy = 2); checking (present = 0, reduced 159 
= 1, absent = 2); posture (normal = 0, abnormal trunk +1, abnormal tail + 1, abnormal limbs + 1, 160 
flexed = 4); balance (normal = 0, impaired = 1, unstable = 2, spontaneous falls = 3); reaction to 161 
stimuli (normal = 0, reduced = 1, slow = 2, absent = 3); vocalisation (normal = 0, reduced = 1, absent 162 
= 2); motility (normal = 0, bradykinesia = 1, akinesia = 2). These values were summed, a maximum 163 
score of 18 indicating severe motor disability, a minimum score of 0 indicating maximum reversal of 164 
motor disability. 165 
 166 
Dyskinesia 167 
Dyskinesia was assessed simultaneously with motor disability by experienced observers blinded to 168 
treatment. The following established dyskinesia rating scale was used; 0 = absent; 1= mild, fleeting 169 
and rare dyskinetic postures and movements; 2 = moderate: more prominent abnormal movements, 170 
but not significantly affecting normal behaviour; 3 = marked, frequent and at times continuous 171 
dyskinesia affecting the normal pattern of activity; 4 = severe, virtually continuous dyskinetic 172 
activity, disabling to the animal and replacing normal behaviour.  173 
 174 
Data handling and statistical analysis 175 
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The area under the curve (AUC) for locomotor activity, motor disability and dyskinesia was 176 
determined from the time course data over 5 hours following drug administration (GraphPad Prism 177 
version 8.0.0 for Windows, GraphPad Software, San Diego California USA, www.graphpad.com). The 178 
AUC for locomotor activity and dyskinesia was calculated from values greater than baseline and for 179 
reversal of motor disability values lower than baseline. For AUC figures therefore, increased 180 
locomotor activity, reversal of motor disability and increased severity of dyskinesia are all 181 
represented by rising values.  182 
 183 
Prior to analysis, motor disability and dyskinesia data were transformed by y = √y in order to 184 
normalise distribution[33]. This transformation allowed the application of parametric tests to scored 185 
data. Time course data was analyses by 2-way ANOVA.  If the effect of treatment was significant, 186 
individual differences at each time point were analysed by Dunnett’s test.  Repeated measures 1-187 
way ANOVA with Sidak's multiple comparisons test was applied to area under the curve (AUC) data, 188 
comparing each group to its respective vehicle condition (L-DOPA alone and LSP1-2111 alone 189 
compared to the vehicle/vehicle condition and L-DOPA with 1, 3 or 6mg/kg LSP1-2111 compared to 190 
L-DOPA alone). 191 
 192 
Results 193 
Vehicle treatment had no effect on either locomotor activity or motor disability and did not induce 194 
dyskinesia expression (Fig 1-3).   195 
 196 
As expected, the submaximal dose of L-DOPA (8 mg/kg p.o.) produced a small but significant rise in 197 
locomotor activity (Fig 1a,b), a significant reversal of motor disability (Fig 2a,b) and significant 198 
expression of dyskinesia (Fig 3a,b).  Locomotor activity peaked at 60 min (Fig 1a), whilst the 199 
improvement in motor disability showed maximum effect between 30 and 90 min after 200 
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administration (Fig 2a) with scores of 2.  Dyskinesia peaked between 90 and 120 min with moderate 201 
to marked dyskinetic movements (median scores of 2-3).  This effect of L-DOPA lasted approximately 202 
3 h.   203 
 204 
LSP1-2111 alone (6 mg/kg s.c.) had no effect on locomotor activity (Fig 1a,b) but significantly 205 
improved motor disability with a sub-maximal reduction in score between 30 and 60 min (Fig 2a,b).  206 
Interestingly, LSP1-2111 (6 mg/kg s.c.) did not induce any dyskinesia (Fig 3a,b). 207 
 208 
When given in combination with L-DOPA (8 mg/kg p.o.), LSP1-2111 (1-6 mg/kg) appeared to increase 209 
locomotor activity in a dose-related manner, although this effect was not significant (Fig 1a,b). In 210 
spite of the reversal of motor disability by LSP1-2111 (6 mg/kg s.c.) alone, when given in 211 
combination, LSP1-2111 (1-6 mg/kg s.c.) did not alter the L-DOPA-induced reversal of motor 212 
disability (Fig 2a,b). However, in parallel with the non-significant rise in locomotor activity, LSP1-213 
2111 produced a non-significant increase in the expression of L-DOPA-induced dyskinesia at the 214 
highest dose tested (Fig 3a,b).  This included a dose-related increase in chorea, but not dystonia 215 
(Supplementary Figure 1) with fleeting bouts of severe choreic activity at peak effect after the 216 
combination of LSP1-2111 (6 mg/kg) and L-DOPA.  For this reason, the effects of further increments 217 
in dose of LSP1-2111 were not explored.     218 
 219 
Discussion 220 
This study set out to examine whether the mGluR4 agonist, LSP1-2111, provided antiparkinsonian 221 
relief or reduced the expression of established LID in the MPTP-treated marmoset. LSP1-2111 alone 222 
was shown to significantly reduce motor disability in parkinsonian animals without causing 223 
dyskinesia. However, LSP1-2111 did not reduce established LID when co-administered with L-DOPA. 224 
 225 
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Regarding the potential antiparkinsonian efficacy of LSP1-2111, the significant reduction in motor 226 
disability seen with LSP1-2111 alone compared to vehicle treatment supports an antiparkinsonian 227 
effect of this mGluR4 agonist. Although the reduction in motor disability was non-significantly lower 228 
than that achieved with L-DOPA treatment, these animals were clearly ‘switched on’ as defined by a 229 
score of 8[34]. Importantly, in contrast to the response with L-DOPA, this beneficial effect of LSP-230 
2111 was not accompanied by a significant increase in locomotor activity, indicating less 231 
hyperactivity, and more naturalistic antiparkinsonian effect. Furthermore, administration of LSP1-232 
2111 alone did not evoke the expression of dyskinesia in L-DOPA-primed animals.  233 
   234 
LSP1-2111 did not have any significant additive effects in reversing motor disability when given 235 
alongside the submaximal dose of L-DOPA (8 mg/ kg) used here. This suggests that the LSP1-2111 236 
operates via the same downstream mechanism as L-DOPA to achieve this antiparkinsonian response. 237 
Existing evidence points towards a mechanism involving modulation of indirect pathway of the basal 238 
ganglia to counteract pathological alterations in firing. For example, in vitro slice work has shown 239 
that activation of mGluR4 receptors, using either agonists or PAMs, reduces GABAergic transmission 240 
across the striatopallidal pathway, reflecting the heteroreceptor role of these receptors[35–37] and 241 
glutamatergic transmission across the subthalamonigral[22,38] and corticostriatal[24,37] pathways, 242 
reflecting the autoreceptor roles.  The outcome of each of these actions is to reduce the overall 243 
activity in the indirect pathway, restoring the balance of firing between the direct and indirect 244 
pathways which is thought to be disrupted in PD[39,40], thereby restoring motor function.  245 
 246 
In contrast to the antiparkinsonian effect of LSP1-2111 noted here, treatment with the mGluR4 247 
PAM, PXT002331, did not elicit a robust antiparkinsonian effect when given alone to MPTP-treated 248 
macaques modelling either early or late stage PD[26]. While this may reflect differences between 249 
the macaque and marmoset models of PD, a more likely explanation is that mGluR4 agonists provide 250 
greater activation of the relevant receptors. To activate mGluR4, an orthosteric agonist like LSP1-251 
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2111 does not require additional endogenous glutamate. However, a PAM such as PXT002331 252 
requires the presence of endogenous glutamate to stimulate the orthosteric site, before the action 253 
of the PAM is manifest. Although sufficient glutamate might be anticipated at the corticostriatal and 254 
subthalamonigral synapses to support actions of a PAM, this is unlikely to be so at the GABAergic 255 
striatopallidal synapse. Therefore, one possible explanation why the mGluR4 agonist but not PAM is 256 
antiparkinsonian when administered alone, is that the additional activity of the agonist at the 257 
striatopallidal synapse is key to underpinning the antiparkinsonian efficacy.  258 
 259 
Although not effective when administered alone, the mGluR4 PAM, PTX002331, did enhance the 260 
locomotor response to L-DOPA[26] and this L-DOPA sparing action was also not accompanied by the 261 
emergence of dyskinesia. In partial agreement with this, in the present study LSP1-2111 tended to 262 
enhance the locomotor activity AUC with L-DOPA from 3134±999 counts/5 h (L-DOPA alone) to 263 
5395±1440 counts/5 h (L-DOPA plus 6 mg/kg LSP1-2111) although this failed to reach significance. 264 
However, an L-DOPA sparing action per se was not examined in this study. This would have required 265 
administering LSP1-2111 with a subthreshold dose of L-DOPA. Given our primary aim was to explore 266 
the anti-dyskinetic effect of LSP1-2111, it was only given here alongside suprathreshold doses of L-267 
DOPA that elicited significant dyskinesia.  Nevertheless, our data provide support for mGluR4 268 
agonists being more effective than PAMs as a monotherapy, while PAMs may prove more effective 269 
as an adjunct to L-DOPA.  270 
 271 
A second aim of this study was to examine the potential of LSP1-2111 to reduce LID in MPTP-treated 272 
marmosets. The present data clearly show that LSP1-2111 has no antidyskinetic effect. At all doses 273 
tested, co-administration of LSP1-2111 failed to reduce the extent of LID compared to that evoked 274 
by administration of L-DOPA alone. Rather, LSP1-2111 tended to increase the expression of LID from 275 
a median AUC score/5 h of 12.5 (range 18; L-DOPA alone) to 17.5 (range 11; L-DOPA plus 6 mg/kg 276 
LSP1-2111).  Although this failed to reach significance, a dose-related increase in choreic movements 277 
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was observed, and prevented higher doses being tested. This lack of antidyskinetic effect agrees 278 
with previous studies in rodents which also found no beneficial effect of a single administration 279 
LSP1-2111 to animals with pre-established dyskinesia[25,27]. Given that plasticity across the 280 
corticostriatal synapse is central to the pathophysiology of LID[6–9], the lack of antidyskinetic 281 
efficacy with LSP1-2111 suggests that modulation across this synapse using an mGluR4 agonist is not 282 
likely to have a functional outcome in vivo. Accordingly, this also points to effects at either the 283 
striatopallidal synapse (as previously discussed) or subthalamonigral synapse underlying the above 284 
antiparkinsonian actions of LSP1-2111, rather than an action on the corticostriatal synapse. 285 
 286 
In contrast to the lack of antidyskinetic efficacy with LSP1-2111, the single published primate study 287 
with an mGluR4 PAM (PTX002331) did reveal an antidyskinetic effect in a macaque model of late 288 
stage PD expressing established LID[26]. The reason behind these different outcomes with agonist 289 
versus PAM remains to be established. One possibility is that a modulatory action on the relevant 290 
mGluR4 receptors -most likely those at the corticostriatal synapse for dyskinesia – is more likely to 291 
normalise firing levels compared to outright activation with an agonist which might instead lead to 292 
too much inhibition of glutamate release and excessively reduced firing in downstream pathways. 293 
An alternative explanation is that the mGluR4 agonist may act at multiple sites in the striatum that 294 
counteract each other. For example, a related mGluR4 agonist, LSP1-3081 has been shown to inhibit 295 
GABA release in the striatum, as well as glutamate release[41]. If LSP1-2111 acts similarly on 296 
heteroreceptors to reduce GABA release in the striatum, this could counter any potential 297 
antidyskinetic efficacy of LSP1-2111’s action on the corticostriatal pathway. Depending on the 298 
location of these heteroreceptors, it is plausible that they are not modulated by an mGluR4 PAM, 299 
due to a lack of sufficient glutamate at the orthosteric site, permitting the antidyskinetic effects of 300 
the PAM to prevail. 301 
 302 
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When administered to rodents in combination with L-DOPA, LSP1-2111 did reduce LID induction in 303 
one[27] but not another[25] study. It will therefore be important in the future to determine whether 304 
this mGluR4 agonist can reduce the incidence or severity of LID when given in combination with L-305 
DOPA in de novo treated marmosets. Such an outcome is also not yet known for mGluR4 PAMs. 306 
 307 
One potential disadvantage of mGluR4 agonists over PAMs that requires consideration is the risk of 308 
triggering receptor desensitisation with chronic use. However, given that chronic administration of 309 
LSP1-2111 was efficacious in a rodent model of LID[27], it seems that desensitisation may not be of 310 
concern with this agonist. Indeed, studies have shown that desensitisation of mGluR4 is independent 311 
of agonist activation[42], thus mGluR4 agonists remain serious contenders for use in PD.   312 
 313 
Summary 314 
In summary, this study is the first to examine the antiparkinsonian and antidyskinetic efficacy of an 315 
mGluR4 agonist in a primate model of PD. Although unable to reduce the severity of established LID, 316 
our data reveal that LSP1-2111 produces an anti-parkinsonian effect, without provoking dyskinesia 317 
in L-DOPA primed MPTP-treated marmosets, supporting further examination of the potential of 318 
mGluR4 agonists in the treatment of PD.   319 
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Supplementary Figure 1.  453 
When given in combination with L-DOPA, LSP1-2111 produced a dose -related increase in chorea but 454 
not dystonia.  455 
 456 
 457 
 458 
Figure shown the effect of treatment with L-DOPA (8 mg/kg p.o.) alone (vehicle) and in combination 459 
with increasing doses of ((2S)-2-amino-4-(hydroxy(hydroxy(4-hydroxy-3-methoxy-460 
nitrophenyl)methyl)phosphoryl)butanoic acid) (LSP1-2111; 1, 3 and 6 mg/kg p.o.) on A) peak chorea 461 
score and B) Peak dystonia score.  Data are presented as median (line) and individual counts. * 462 
p<0.05 (Friedman's one-way ANOVA). 463 
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Figure Legends 466 
 467 
Figure 1. The effect of treatment with ((2S)-2-amino-4-(hydroxy(hydroxy(4-hydroxy-3-methoxy-468 
nitrophenyl)methyl)phosphoryl)butanoic acid (LSP1-2111; 6 mg/kg p.o.) alone or with L-DOPA in the 469 
presence of increasing doses of LSP1-2111 (vehicle, 1, 3 and 6 mg/kg p.o.) on locomotor activity. A) 470 
The time course of effect with treatment administered at time T=0. Data are presented as mean 471 
locomotor counts per 30 minutes (n=6). * p < 0.05 versus vehicle alone (two-way ANOVA plus Holm-472 
Sidak’s multiple comparison test on transformed data). B) Total locomotor activity counts (AUC). 473 
Data are presented as mean (line) and individual counts. * p<0.05 versus vehicle alone (    ) (one-way 474 
ANOVA plus Holm-Sidak’s multiple comparison test on transformed data). 475 
 476 
Figure 2. The effect of treatment with ((2S)-2-amino-4-(hydroxy(hydroxy(4-hydroxy-3-methoxy-477 
nitrophenyl)methyl)phosphoryl)butanoic acid (LSP1-2111; 6 mg/kg p.o.) alone or with L-DOPA in the 478 
presence of increasing doses of LSP1-2111 (vehicle, 1, 3 and 6 mg/kg p.o.) on motor disability. A) The 479 
time course of effect with treatment administered at time T=0. Data are presented as median scores 480 
per 30 minutes (n=6). * p < 0.05 all groups versus vehicle alone, NS indicates single point of non-481 
significance (two-way ANOVA plus Holm-Sidak’s multiple comparison test on transformed data).  482 
B) Total reversal of motor disability (AUC). Data are presented as median (line) and individual counts. 483 
* p<0.05 versus vehicle alone (    ) (one-way ANOVA plus Holm-Sidak’s multiple comparison test on 484 
transformed data). 485 
 486 
Figure 3. The effect of treatment with ((2S)-2-amino-4-(hydroxy(hydroxy(4-hydroxy-3-methoxy-487 
nitrophenyl)methyl)phosphoryl)butanoic acid (LSP1-2111; 6 mg/kg p.o.) alone or with L-DOPA in the 488 
presence of increasing doses of LSP1-2111 (vehicle, 1, 3 and 6 mg/kg p.o.) on dyskinesia expression. 489 
A) The time course of effect with treatment administered at time T=0. Data are presented as median 490 
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scores per 30 minutes (n=6). + p < 0.05 vehicle versus L-DOPA alone, * p < 0.05 vehicle versus L-491 
DOPA plus LSP1-2111 combinations (two-way ANOVA plus Holm-Sidak’s multiple comparison test on 492 
transformed data). B) Total dyskinesia score (AUC). Data are presented as median (line) and 493 
individual counts. * p<0.05 versus vehicle alone (    ) (one-way ANOVA plus Holm-Sidak’s multiple 494 
comparison test on transformed data). 495 
 496 
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Figure 1. 498 
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Figure 2. 501 
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Figure 3. 505 
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